Myelodysplastic Syndrome (MDS) Drugs Market Report 2026

Myelodysplastic Syndrome (MDS) Drugs Market Overview

• Myelodysplastic Syndrome (MDS) Drugs market size has reached to $3.7 billion in 2025 • Expected to grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Rising Incidences Of Myeloid Leukemia Boosts Myelodysplastic Syndrome (MDS) Drug Treatment Market • Market Trend: Innovative Drug Development And Approvals Transform Myelodysplastic Syndrome (MDS) Treatment Market • North America was the largest region in 2025.

What Is Covered Under Myelodysplastic Syndrome (MDS) Drugs Market?

Myelodysplastic syndrome (MDS) drugs are medications used to treat myelodysplastic syndrome, a collection of several bone marrow illnesses in which the bone marrow fails to create enough healthy blood cells. They work by helping to restore normal gene function in bone marrow cells and produce more red blood cells. The main types of myelodysplastic syndrome (MDS) drugs are chemotherapy and immunomodulatory drugs. Chemotherapy refers to a type of cancer therapy that employs anti-cancer medications to eradicate cancerous cells. They are administered through oral and parenteral routes for the treatment of refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with ringed sideroblasts by various end users such as hospitals, clinics and ambulatory surgical centers.

What Is The Myelodysplastic Syndrome (MDS) Drugs Market Growth Forecast?

The myelodysplastic syndrome (mds) drugs market size is expected to see strong growth in the next few years. It will grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of novel immunomodulatory drugs, rising adoption of precision medicine in hematology, expansion of clinical trial pipelines, growing focus on improving patient quality of life, increasing healthcare spending on rare diseases. Major trends in the forecast period include increasing use of targeted therapeutic regimens, rising adoption of oral and parenteral combination therapies, growing focus on personalized treatment approaches, expansion of supportive care therapies, enhanced monitoring of treatment outcomes.

What Are The Drivers Of The Myelodysplastic Syndrome (MDS) Drugs Market?

The increasing incidences of myeloid leukemia are expected to propel the growth of the myelodysplastic syndrome (MDS) drug treatment market going forward. Myeloid leukemia is a type of cancer that originates in the bone marrow and affects the cells responsible for producing various kinds of blood cells. Myelodysplastic syndrome (MDS) drugs aim to improve bone marrow function by targeting the root cause of leukemia to reduce the risk of complications with low blood cell counts, reduce the need for chemotherapy and transplants, and improve the survival rates for people with myelodysplastic syndrome (MDS) drugs. For instance, in January 2023, according to the estimates of the American Cancer Society, a US-based voluntary health organization, there were about 20,380 cases and 11,310 deaths of acute myeloid leukemia (AML) will be in adults during 2023. Therefore, the increasing incidences of myeloid leukemia drive the myelodysplastic syndrome (MDS) drug industry. The rising research and development is expected to propel the growth of the myelodysplastic syndrome (MDS) drugs market going forward. Research and development refers to systematic scientific investigation and experimentation activities aimed at discovering, creating, and improving new therapeutic agents and treatment approaches. Research and development are rising due to increasing understanding of MDS molecular pathogenesis and genetic mutations, which have enabled pharmaceutical companies and research institutions to identify novel therapeutic targets and develop precision medicine approaches for this heterogeneous disease. Rising research and development directly contribute to growth by expanding the pipeline of investigational therapies, leading to new drug approvals that provide additional treatment options for patients who fail standard hypomethylating agent therapy or require alternative interventions. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, rising research and development is driving the growth of the myelodysplastic syndrome (MDS) drugs industry.

Key Players In The Global Myelodysplastic Syndrome (MDS) Drugs Market

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Global Myelodysplastic Syndrome (MDS) Drugs Market Trends and Insights

Major companies operating in the myelodysplastic syndrome (MDS) drugs market focus on developing new products such as targeted therapy to improve patient outcomes, meet specific customer needs, and fit the ecosystem. Targeted therapy for myelodysplastic syndromes (MDS) involves using drugs that specifically target genetic mutations or molecular abnormalities in cancer cells, aiming to improve outcomes by selectively attacking abnormal cells while minimizing damage to healthy tissue. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of Tibsovo for this new indication was evaluated in an open-label, single-arm, multicenter study of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

What Defines the Myelodysplastic Syndrome (MDS) Drugs Market?

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myelodysplastic Syndrome (MDS) Drugs Market Report 2026?

The myelodysplastic syndrome (mds) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome (mds) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.